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In adenovirus E4 mutant infections, viral DNAs form concatemers through a process that requires host
Non-homologous End Joining (NHEJ) proteins including DNA Ligase IV (LigIV). Adenovirus proteins E4
34k and E1b 55k form the substrate-selection component of an E3 ubiquitin ligase and prevent
concatenation by targeting LigIV for proteasomal degradation. The mechanisms and sites involved in
targeting this and other E3 ligase substrates generally are poorly-understood. Through genetic analysis,
we identiﬁed the a2 helix of one LigIV BRCT domain (BRCT-1) as essential for adenovirus-mediated
degradation. Replacement of the BRCT domain of DNA ligase III (LigIII), which is resistant to
degradation, with LigIV BRCT-1 does not promote degradation. A humanized mouse LigIV that
possesses a BRCT-1 a2 helix identical to the human protein, like its parent, is also resistant to
adenovirus-mediated degradation. Thus, both the BRCT-1 a2 helix and an element outside BRCT-1 are
required for adenovirus-mediated degradation of LigIV.
& 2012 Elsevier Inc. All rights reserved.Introduction
Among the most common post-translational modiﬁcations
employed by eukaryotic cells to regulate protein levels and
activities is ubiquitination, covalent attachment of the 8 kDa
ubiquitin protein to a lysine residue in the ubiquitinated protein.
Ubiquitination of a protein can alter its stability, localization and
participation in protein–protein interactions.
Proteins can be conjugated to single ubiquitin moieties (mono-
ubiquitination) or to ubiquitin chains (polyubiquitination). Within
polyubiquitin chains, each ubiquitin is connected by its C-terminal
glycine to one of the seven lysines (K6, K11, K27, K29, K33, K48, and
K63) in the preceeding ubiquitin. Proteins modiﬁed by polyubiquitin
chains of four or more linked via K48 are degraded by the 26S
proteasome. Targeted destruction of proteins by the ubiquitin/
proteasome pathway is an essential process that is conserved among
all eukaryotes (Woelk et al., 2007). Disruption of the ubiquitination/ll rights reserved.
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mistry and Pharmacognosy,
go, Rockford Health Scienceproteasome pathway can be lethal to individual cells or lead to
protein buildup and diseases such as Alzheimer’s, Parkinson’s, and
Huntington’s diseases (Ciechanover and Iwai, 2004).
Modiﬁcation of a target protein by ubiquitin occurs in three
stages. First, ubiquitin is activated in an ATP-dependent manner
through covalent attachment to one of two E1 activating
enzymes, Ube1 (Uba1) (Haas et al., 1982) and Uba6 (Jin et al.,
2007) in mammalian cells, by a thioester bond. Activated ubiqui-
tin can then be transferred to any of at least 40 E2 ubiquitin
conjugating enzymes [Pfam Pf00179 ubiquitin conjugation
enzyme family (Finn et al., 2010)]. Finally, ubiquitin is transferred
to its intended target by one of several hundred E3 ubiquitin
ligases (Li et al., 2008), which act as target selectors. There are two
classes of E3s. Roughly 95% of human E3’s are within the RING
family (Li et al., 2008), which contain a RING (Really Interesting
New Gene) ﬁnger subunit that binds the E2 (Petroski and
Deshaies, 2005). The ubiquitin linked to the E2 enzyme is
transferred directly onto the substrate without any Ub–E3 inter-
mediate (Deshaies and Joazeiro, 2009). The remaining E3 com-
plexes contain a HECT (Homologous to E6-AP C-Terminus)
domain, and form a covalent intermediate with ubiquitin before
transference to the target (Rotin and Kumar, 2009).
The ubiquitination pathway is hijacked by many viruses to
make the cellular environment more permissive for viral replica-
tion. Adenovirus type 5 (Ad5) (Harada et al., 2002), Herpesviruses
(Epstein Barr Virus (Sato et al., 2009), murid Herpesvirus
(Rodrigues et al., 2009), and Kaposi’s Sarcoma associated Herpes-
virus (Cai et al., 2006)) and Human Immunodeﬁciency Virus (HIV)
Fig. 1. DNA Ligases. (A) Domains of the DNA ligase family proteins. DNA Ligases I,
III, and IV constitute the mammalian DNA ligase family. All three members have a
DNA binding domain (DBD), adenylation domain (AdD), and oligonucleotide
binding domain (OBD). DNA Ligases III and IV both contain BRCA C-terminus
(BRCT) domains at their C-terminus. Ligase III has a zinc ﬁnger (ZnF) domain and
Ligase I has a nuclear localization signal (NLS) and proliferating cell nuclear
antigen (PCNA) binding domain at the N-terminus. The amino acid position (Cole
et al., 2008) of each domain is indicated above each diagram. (B) LigIV truncation
mutants. All mutants have an N-terminal myc tag and encompass the amino acids
indicated in the name. The bars represent the conserved ATP-dependent ligase
domains; ovals are BRCT domains. (C) Degradation of LigIV truncation mutants by
adenovirus. LigIV mutant plasmids were transfected into 293 cells which were
subsequently either mock infected () or infected with H5dl1013 (þ) for 20 h.
Cells were lysed, equal amounts of protein were loaded onto a polyacrylamide gel,
and tagged LigIV was visualized by immunoblotting for the myc tag. The loading
control is actin, and p53 is a control for adenovirus ubiquitin ligase function.
U: Untransfected cells.
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ing Cullin 5-containing RING ﬁnger E3s to ubiquitinate novel
targets that would otherwise interfere with virus propagation. In
uninfected cells, Cullin 5 forms a complex with Elongin B, Elongin
C, and Rbx1 to create a complete E3 ubiquitin ligase complex that
targets Dab1 (Feng et al., 2007), ErbB2 (Ehrlich et al. 2009), Hif1-a
(Ehrlich et al. 2009), Rbp1 (Harreman et al., 2009; Yasukawa et al.,
2008) and Estrogen Receptor (ERa) (Johnson et al., 2006) for
degradation. Upon Ad5 infection, two early proteins, E4 34k
(product of E4 ORF 6) and E1b 55k, associate with the Cullin
5/Elongin B/Elongin C/Rbx1 complex to target novel proteins
including p53 (Querido et al., 1997), Mre11 (Stracker et al.
2002), DNA Ligase IV (LigIV) (Baker et al., 2007), BLM (Orazio
et al., 2011), and integrin a3 (Dallaire et al., 2009) for ubiquitina-
tion and subsequent degradation. E4 34k binds to the E3 complex
through its association with Elongin B/C by means of its three
BC-box motifs (Blanchette et al., 2004; Ying Cheng et al., 2007).
E1b 55k selects and binds the target protein and brings them to
the E3 ligase through complex formation with E4 34k. Details of
how these host proteins are recognized and targeted for degrada-
tion, however, remain unknown.
Three of the ﬁve proteins targeted for degradation by the Ad5
ubiquitin ligase are involved in the recognition and subsequent
repair of DNA double-strand breaks through Non-Homologous
End Joining (NHEJ). Mre11 (Rupnik et al., 2009) and p53
(Sengupta and Harris, 2005) are involved early in the DNA repair
pathway and act as sensors of DNA damage, and LigIV is essential
in the last joining step in the NHEJ pathway (Wilson et al., 1997;
Critchlow et al., 1997). The presence of viral DNA in infected cells
is sufﬁcient to initiate a DNA damage response (Karen et al., 2009)
which results in NHEJ mediated adenoviral genome ligation.
Because the resultant concatamerized genomes are too large to
be packaged into the viral capsid (Bett et al., 1993), the inhibition
of NHEJ is essential for viral propagation. Viruses frequently have
built-in redundancy for processes that are crucial for viral
propagation, and the multiple routes by which adenoviruses
inhibit the DNA damage response at both early and late steps
clearly show that inhibition of DNA repair is vital to adenovirus
infection.
DNA Ligase IV (LigIV) is a member of the ATP-dependent DNA
ligase family. Members of this family all contain a DNA binding
domain (DBD), adenylation domain (AdD), and oligonucleotide
binding domain (OBD), which together constitute 70% of each
protein (Fig. 1A) (Pascal et al., 2004; Wei et al., 1995; Cotner-
Gohara et al., 2008). Other members of the DNA ligase family
include DNA Ligase I, which has the crucial role during DNA
replication of ligating together Okazaki fragments (Henderson
et al., 1985; Barnes et al., 1992), and DNA Ligase III (LigIII) which
has a role in nucleotide excision repair (NER) (Moser et al., 2007).
Within the DNA ligase family, only LigIV is targeted for degrada-
tion by adenovirus. How LigIV is speciﬁcally recognized by
adenovirus is unknown.
Our hypothesis is that a unique structure or amino acid
sequence within LigIV, which is absent from the other DNA
ligases, is recognized by adenoviral proteins E4 34k and E1b 55k
and confers sensitivity to degradation in adenovirus infection. The
purpose of this study was to identify these recognition elements.
Through truncation analysis, a minimal targeting region sufﬁcient
for degradation of LigIV by adenovirus was identiﬁed. High
resolution mapping through the use of site-directed mutagenesis
identiﬁed an alpha helix within the ﬁrst BRCT domain of LigIV
(BRCT-1) that is critical for degradation and which is absent in
other DNA Ligase family members, providing an explanation for
LigIV speciﬁcity. This alpha helix, however, is not sufﬁcient for
targeted degradation, since neither its insertion into LigIII nor
fusion of LigIV’s full-length BRCT-1 domain to LigIII targets thechimeric protein for degradation. Therefore, additional recogni-
tion elements exist in LigIV.Results
Localization of the targeting domain in LigIV. To identify regions in
LigIV essential for recognition by the adenovirus ubiquitin ligase, a
series of myc-tagged LigIV truncationmutants (Costantini et al., 2007)
(Fig. 1B) were examined for susceptibility to degradation during Ad5
infection. 293 cells transfected with each truncation mutant were
mock infected or infected with H5dl1013 (Bridge and Ketner (1989)),
an Ad5mutant which is deleted for E4 ORFs 1–3 and overproduces E4
34k. Levels of the myc-tagged truncated LigIV proteins were deter-
mined by immunoblotting at 20 h post infection (p.i) (Fig. 1C). Actin
served as a loading control, and degradation of endogenous p53 as a
control for successful adenovirus infection. Truncated proteins con-
taining amino acids 1–790 (myc-LigIV 1–790), 1–748 (myc-LigIV
Fig. 3. Site directed mutagenesis of LigIV BRCT-1. (A) Structure of the BRCT-1
domain of human LigIV (PDB ID: 2E2W (Nagashima et al. 2006), rendered by
Pymol) with the amino acids that differ from the canine sequence indicated in
wire frame format. (B) Structure of the BRCT-1 domain of LigIV with solvent-facing
amino acids in the a2 helix indicated in wire frame format. (C) and (D) 293 cells
were transfected with myc-tagged LigIV 600–911-based expression plasmids
containing amino acid substitutions at the indicated positions. Four hours after
transfection, cells were either mock infected (M), infected with adenovirus (Ad), or
T. Gilson et al. / Virology 428 (2012) 128–1351301–748), and 600–911 (myc-LigIV 600–911) were all degraded as
efﬁciently as full length LigIV. In contrast, the protein truncated at
residue 643 (LigIV 1–643) was not degraded. These results indicate
that the region 643–748 contains an element necessary for LigIV
recognition by the adenovirus ubiquitin ligase complex. They also
suggest that the larger region 600–748 contains elements sufﬁcient
for LigIV degradation.
Fine-structure mapping of recognition elements. BRCT domains,
such as that contained within LigIV 643–748, frequently partici-
pate in protein–protein interactions (Rodriguez, 2008) and there-
fore LigIV BRCT-1 is a likely site of interactions that mediate
degradation by the adenovirus ubiquitin ligase. Mutation of
amino acids that directly participate in interactions with the
adenovirus ubiquitin ligase are predicted to interfere with LigIV
degradation. Therefore, to deﬁne the elements that are essential
for adenovirus-mediated degradation of LigIV, we examined
degradation of a series of LigIV mutants with amino acid sub-
stitutions within the region 600–748.
To guide selection of mutation sites within BRCT-1, we took
advantage of the observation that although human and canine
LigIV proteins are very similar in amino acid sequence (Fig. 2A),
canine LigIV is not degraded in Ad5 infected MDCK cells (Fig. 2B).
Both canine and human Mre11 are efﬁciently degraded during
Ad5 infection (Fig. 2B), which indicates that the Ad5 E4 34k and
E1b 55k proteins interact successfully with canine Cullin 5 and
Elongins B and C to form a functional ubiquitin ligase. We
therefore attribute the lack of canine LigIV degradation to differ-
ences between canine and human LigIV in essential elements that
mediate recognition by the adenovirus ubiquitin ligase or ubiqui-
tination sites. Within the BRCT-1 region, canine and human LigIV
differ at four positions, which are indicated in bold in Fig. 2A and
shown as wire frames on the ribbon diagram of the human LigIV
BRCT-1 domain in Fig. 3A. Because the tops of BRCT domains tend
to participate in protein–protein interactions (Rodriguez, 2008) itFig. 2. LigIV homologs. (A) Alignment of the amino acid sequences of the BRCT-1
domains of human, canine, and murine DNA LigIV. Amino acids that diverge from
the human sequence are indicated in bold. The four changes present in canine
LigIV, also present in mouse and rat (not shown), are indicated by arrows with
position in the human protein indicated beneath. (B) Canine DNA LigIV is not
degraded in adenovirus infection. Extracts of MDCK canine kidney cells infected
with adenovirus were fractionated by SDS PAGE and immunoblotted for LigIV,
Mre11, p53, and actin. Mre11 and p53 are efﬁciently degraded, indicating that the
viral ubiquitin ligase functions in canine cells, but LigIV is not.
infected with a deletion mutant adenovirus that does not express E4 genes (DE4).
Cells were harvested 20 h post infection, lysed, and 20 mg soluble protein was run
on a polyacrylamide gel that was immunoblotted for myc, actin (C and D), and
p53 (D).is of interest that two of the amino acids altered in canine DNA
LigIV (673 and 724) are within this region. Human LigIV Q673
also is part of the SQ consensus DNA PK phosphorylation site
(Lees-Miller et al., 1990), and human LigIV is phosphorylated at
S672 (Wang et al., 2004). Phosphorylation of this residue could
affect ubiquitination (Catic et al., 2004) or interaction with the
adenovirus ubiquitin ligase. Canine LigIV contains H in the
corresponding position, and is not likely to be phosphorylated
there. The remaining two amino acid differences occur at residue
735, located at the opposite end of BRCT-1, and 714, which lies in
the structurally conserved a2 helix. Mouse LigIV also contains
substitutions at these amino acids (Fig. 2A) and similarly is not
degraded by adenovirus (data not shown).
If any of these four amino acids are essential for LigIV targeted
degradation, mutations of human myc-LigIV 600–911 that change
the critical residue to that found in canine LigIV should prevent
degradation by adenovirus. Expression plasmids bearing individual
mutations (Q673H, L714S, A724E, and F735C) were introduced into
293 cells by transfection. Transfected cells subsequently were either
mock infected or infected with H5dl1013 and mutant protein levels
were assayed in extracts by immunoblotting with anti c-myc
(Fig. 3C). LigIV Q673H was not detected in transfected cells, and
we therefore introduced the mouse 673Y mutation into myc-LigIV
600–911 to assess the role of residue 673 in targeted degradation.
Three mutants (Q673Y, A724E, and F735C and the double mutant
Q673Y/A724E) were degraded by adenovirus as efﬁciently as control
LigIV 600–911. The fourth, L714S was not.
Fig. 4. Degradation of Ligase III/Ligase IV fusions in adenovirus infection. (A) 293
cells were transfected with DNAs encoding wild type LigIV and LigIII, or the fusion
proteins LigIII 1–787/LigIV 600–748 (BRCT-1), LigIII 1–787/LigIV 600–911 (BRCT-
1þ2), and LigIII/LigIV 703–720 (a2). Four hours after transfection, cells were
either mock infected () or infected with adenovirus (þ). Cells were harvested
20 h post infection, lysed, and 20 mg soluble protein was loaded onto a poly-
acrylamide gel that was immunoblotted for myc, actin, and p53. (B) Diagrams of
the fusion proteins. LigIV sequences are colored white; LigIII sequences dark gray.
Insertion of the LigIV BRCT1 a2 helix in LigIII-a2 is indicated by the white bar.
ZnF: LigIII zinc ﬁnger region.
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the a2 helix is an essential element in recognition of LigIV by the
adenovirus ubiquitin ligase. To test this hypothesis, three addi-
tional residues in the a2 helix were mutated to alanine and tested
for effects on degradation by adenovirus. As shown in Fig. 3B, I707
and L714 mark the ends of a2 helix and both point directly
outward into solution. Residues K710 and N711 also point into
solution, but slightly to the side. Mutation of I707 individually or
K710 and N711 as a pair was able to prevent degradation by
adenovirus (Fig. 3D). Therefore, the a2 helix is an essential
element in targeting LigIV for degradation.
To explore the possibility that the K710A mutation prevented
LigIV degradation by destroying a ubiquitination site, K710 was
mutated to arginine to prevent ubiquitination but retain charge to
minimize disruption of protein–protein interactions. This substi-
tution had no effect on the ability of adenovirus to target the
protein for degradation (Fig. 3D). Thus, K710 is not an obligatory
ubiquitination site for the adenovirus ubiquitin ligase. Mutagen-
esis has also been performed in the region 600–653, immediately
upstream of BRCT-1. Using myc-LigIV 600–911 as a backbone as
above, multiple-alanine substitution mutations were made in ﬁve
regions predicted to be surface exposed by Jpred (Cole et al.
2008): 600–604, 607–609, 620–625, 625–629, and 644–645,
constituting 55% of the predicted surface residues. None of these
mutations prevented LigIV degradation in adenovirus-infected
cells (Supplementary Fig. S1), indicating that these 20 amino
acids are not essential for recognition and degradation of LigIV.
In all, seven of the 16 lysines within LigIV 600–748 were
individually mutated and none prevented degradation. If the
ubiquitinations site lies within this region, it could be at any of
the nine lysine residues that have yet to be tested. However, the
site at which proteins are modiﬁed by ubiquitin can be promis-
cuous and deletion of one ubiquitination site can cause another
lysine to become ubiquitinated in its place (Roth and Davis, 2000;
Petroski and Deshaies, 2003).
LigIV BRCT-1 or the BRCT-1 a2 helix is not sufﬁcient for adenovirus
mediated degradation. DNA ligase III (LigIII) and LigIV are both
members of the ATP-dependent DNA Ligase family of proteins and
both contain the N-terminal DBD, AdD, and OBD domains as well as
C-terminal BRCT domain(s) (Fig. 1A), but only LigIV is targeted for
degradation (Fig. 1C). Since a fragment containing the ﬁrst and the
second BRCT domains of LigIV (600–911) is efﬁciently degraded by
adenovirus, replacement of LigIII BRCT-1 domain with that region
from LigIV might promote targeting of LigIII for degradation. We
addressed this hypothesis by testing such a DNA LigIII/IV chimeric
protein for susceptibility to degradation by adenovirus infection.
The site selected for fusion within LigIII, at amino acid 787, is
located in a region predicted to be unstructured between the OBD
(LigIII 590–771) and BRCT (LigIII 845–922) domains and where
manipulations should not disrupt secondary or tertiary structure.
Additionally, the region downstream of 787 shows some similarity
to the corresponding region in LigIV (600–653; Supplementary Fig.
S2), further minimizing the chances of structural abnormalities in
the fusion protein. To produce the chimera, LigIV DNA encoding
amino acids 600–911 was PCR ampliﬁed with a primer that added
LigIII 773–787 to the N-terminus, and the fusion DNA was inserted
into LigIII at a unique endogenous restriction enzyme site within
the LigIII segment. The chimera, LigIII/LigIV BRCT 1þ2 (LigIII 1–
787/LigIV 600–911), was transfected into 293 cells that were
subsequently infected with adenovirus. LigIII was not degraded
upon infection with adenovirus, but LigIII/LigIV BRCT-1þ2 was
degraded (Fig. 4). These ﬁndings indicate that in the context of DNA
LigIII, LigIV 600–911 remains sufﬁcient to mediate recognition and
degradation by the adenovirus ligase.
We next wanted to determine whether either the LigIV a2 helix
or LigIV BRCT-1 alone is sufﬁcient to target LigIII for degradation.To test that hypothesis we inserted the LigIV a2 helix into LigIII in
place of the short loop that occupies the corresponding position in
LigIII. After comparison of the crystal structures of LigIII BRCT and
LigIV BRCT-1 and identiﬁcation of equivalent sites and unique
restriction endonuclease sites surrounding the loop and a2 helix,
LigIV 703–720 was inserted between PmlI and BspEI sites within
LigIII to replace amino acids 893 to 904. To address the possibility
that the BRCT-1 domain is sufﬁcient, a LigIII 1–787/LigIV 600–748
chimera was prepared essentially as described above for LigIII 1–
787/LigIV 600–911.
293 cells were transfected with LigIII/LigIV a2 (LigIII1-892/
LigIV 703–720/LigIII 904–922) or LigIII/LigIV BRCT-1 (LigIII 1–
787/LigIV 600–748) and subsequently infected with adenovirus.
In neither case was the chimeric protein a target for adenovirus-
mediated degradation (Fig. 4B). This suggests that neither the a2
helix nor BRCT-1 alone is sufﬁcient to mediate a productive
interaction with the adenovirus ubiquitin ligase. However, it is
unknown if in these chimeric proteins whether the a2 helix in
LigIV BRCT-1 is exposed. When BRCT domains are present in pairs,
as in native LigIV or LigIII 1–787/LigIV 600–911, they usually form
a dimer. In the LigIII fusion proteins, LigIV BRCT-1 is present alone
and cannot dimerize and thus could be oriented differently than
in the presence of LigIV BRCT2. Moreover, the possibility that
steric hindrance from some region of LigIII prevents exposure of
a2 helix cannot be ruled out.
Canine and mouse LigIV are not targeted for degradation by
adenovirus (Figs. 2B and 5). Within the a2 helix, canine and
mouse LigIV present a serine at position 714 in place of the
human LigIV leucine (Fig. 2A). Mutation of human LigIV L714 to
the canine/mouse serine to create L714S prevented degradation
by adenovirus (Fig. 3D). These observations raise the possibility
that the human a2 helix in the context of a mouse or canine LigIV
protein might confer sensitivity to the adenovirus E3 ligase. To
test this hypothesis, the BRCT-1 a2 helix of mouse LigIV was
humanized by mutating S714 to leucine through site directed
mutagenesis. 293 cells were transfected with mouse wild type or
mutant LigIV (mLigIVS714L) and subsequently infected with
Fig. 5. LigIV a2 helix is not sufﬁcient for targeted degradation by adenovirus.
Human LigIV 600–911 was mutated at residue 714 to the mouse amino acid
(L714S), and full-length mouse LigIV was mutated at residue 714 to the human
amino acid (S714L). 293 cells were transfected with wild type (WT) human (600–
911) or mouse (1–911) LigIV and the 714 plasmids. Four hours after transfection,
cells were either mock infected () or infected with adenovirus (þ) for 2 h. Cells
were harvested 20 h post infection, lysed, and 20 mg soluble protein was run on
a polyacrylamide gel that was immunoblotted with anti-myc, anti-p53, and
anti-actin.
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targeted for degradation (Fig. 5). Presence of a human a2 helix
therefore was not sufﬁcient to target mouse LigIV for degradation.
Taken together, these observations indicate that the DNA LigIV
a2 helix contains elements essential for adenovirus-mediated
degradation, but that sequences outside that region are also
required.Discussion
Adenovirus type 5 inhibits the Non-Homologous End Joining
(NHEJ) DNA repair pathway through targeted degradation of DNA
Ligase IV (LigIV) (Baker et al., 2007). Viral proteins E4 34k and E1b
55k capture the host Cullin 5 E3 ubiquitin ligase complex to target
LigIV as well as p53 (Querido et al., 1997), Mre11 (Stracker et al.,
2002), BLM (Orazio et al., 2011), and integrin a3 (Dallaire et al.,
2009) for ubiquitination and subsequent proteasome-mediated
degradation. The structural and sequence elements within these
proteins required for recognition and subsequent degradation by
adenovirus is unknown, aside from p53 (Roth et al., 1998). In this
study, human LigIV was examined to identify the determinants
for targeted degradation and a region that is essential but not
sufﬁcient for adenovirus-targeted degradation was identiﬁed.
LigIV is a member of a family of ATP-dependent DNA ligases,
but only LigIV is targeted for degradation by adenovirus. All three
DNA ligase family members contain recognizable DNA binding
domain (DBD), adenylation domain (AdD), and oligonucleotide
binding domain (OBD) motifs (Fig. 1). However, amino acid
sequence conservation among family members is poor: alignment
of the primary amino acid sequences of DNA ligases I, III and IV
revealed that these proteins share only 23% overall sequence
identity. Thus, protein sequence does not provide clues regarding
the elements that determine the unique susceptibility of DNA
ligase IV to the adenovirus ubiquitin ligase.
To localize the essential targeting elements within the 911aa
LigIV protein we utilized a series of previously described trunca-
tion mutants (Costantini et al., 2007). The shortest truncated
protien (600–911aa) and the N terminal fragment 1–748 wereboth targeted for degradation, suggesting that elements sufﬁcient
for LigIV degradation lie in the region between residues 600 and
748 (Fig. 1C). The ﬁrst BRCT domain of LigIV lies between amino
acids 654 and 748, and our data therefore suggested the hypoth-
esis that BRCT-1 contains elements necessary for adenovirus-
targeted degradation. BRCT repeats are composed of 4 central
beta-sheets surrounded by 3 alpha-helices. Mutation of solvent
exposed amino acids within the second alpha helix (a2) of BRCT-1
prevented degradation by adenovirus (Fig. 3C and D) and con-
ﬁrmed the importance of the a2 helix in targeted degradation of
LigIV by adenovirus. The BRCT-1 a2 helix of LigIV is a unique
feature within the ATP-dependent DNA ligase family. DNA ligase I
lacks BRCT domains entirely and the single BRCT domain of ligase
III (LigIII) contains only the ﬁrst and third a-helices, with a short
loop where LigIV has the a2 helix (Krishnan et al. 2001). The fact
that LigIV alone possesses a a2 helix explains the mechanism by
which LigIV is the only DNA ligase in human cells to be targeted
for adenovirus-mediated degradation.
This a2 helix however is not sufﬁcient to target LigIV for
degradation, since insertion of a2 into LigIII’s BRCT domain and
fusion of LigIV BRCT-1 to LigIII were both unable to promote
degradation of LigIII (Fig. 4). These data suggest that LigIV
sequences that lie outside of the BRCT1 a2 helix are required for
targeted degradation. Since targeted degradation occurs when the
LigIV BRCT-1 domain is accompanied by either LigIV C-terminal
sequences 749–911 or LigIV N-terminal sequences 1–600, each of
those segments individually must contain features that satisfy the
second requirement. Alternatively, the LigIV BRCT-1 a2 helix may
be sufﬁcient to direct adenovirus targeted degradation, but in
LigIII/LigIV fusion proteins with short LigIV segments the critical
a2 helix might be inaccessible due to misfolding of the chimeric
protein and thus unavailable for directing targeted degradation.
These competing interpretations of our data represent two
mutually exclusive hypotheses: (1) the LigIV BRCT-1 a2 helix is
one of at least two determinants for targeted degradation, and (2)
the LigIV BRCT-1 a2 helix is sufﬁcient to target a polypeptide for
degradation, provided it is accessible. To distinguish between
these hypotheses, we used murine LigIV to test the functionality
of the LigIV BRCT-1 a2 helix in the context of a closely-related but
degradation-resistant LigIV protein.
Human and murine LigIV share 92% similarity, and within the
a2 helix, they differ only at the amino acid corresponding to
human LigIV L714, where the murine sequence contains serine, a
substitution shown above to prevent adenovirus-induced degra-
dation. We created a murine LigIV S714L substitution mutant
(mLigIVS714L), which has a BRCT-1 a2 helix that is identical to the
human a2 helix and, signiﬁcantly, is in the context of a native
LigIV polypeptide. Folding of mLigIVS714L is expected to preserve
the overall LigIV structure and, presumably, accessibility of the
BRCT-1 a2 helix. mLigIVS714L is resistant to degradation during
adenovirus infection (Fig. 5). These data clearly demonstrate that
while the a2 helix of LigIV BRCT-1 is one contributing determi-
nant of adenovirus-targeted LigIV degradation, the a2 helix alone
is not sufﬁcient to mediate targeted degradation. Examination of
the 60 remaining residues that are dissimilar between human
and murine LigIV may identify additional determinants for
adenovirus-targeted LigIV degradation.
How might the BRCT1 domain of human LigIV act as a
determinant for E4 34k/E1b 55k dependent polyubiquitination?
BRCT repeats have been characterized as phosphoserine/threo-
nine (pS/T) binding domains (Yu et al., 2003a,b; Williams et al.,
2005) where the TxK motif in the a2 helix and an SG motif
directly after the ﬁrst beta strand (Clapperton et al., 2004;
Rodriguez, 2008) mediate binding to a pS/TxxO (O: hydrophobic)
motif in the binding partner. While human LigIV BRCT-1 contains
only the SG motif, it has been shown to bind to a generic
T. Gilson et al. / Virology 428 (2012) 128–135 133phosphoserine peptide (Yu et al., 2003a,b) and thus LigIV BRCT-1
may participate in phosphorylation-dependent interactions. Phos-
phorylation of both E4 34K and E1b 55K has been observed in vivo
(Boivin et al., 1999), (Takayesu et al., 1994) and both viral proteins
independently bind LigIV (Baker et al., 2007; Jayaram et al., 2008).
Only E4 34K, though, contains consensus BRCT binding sites (68–
71 SVGF, 205–8 SFGY), and the actual sites of E4 34k phosphor-
ylation have yet to be determined. Nevertheless, these data
suggest the testable hypothesis that adenovirus-targeted degrada-
tion of LigIV is mediated by the interaction of phosphorylated
adenoviral proteins with the BRCT repeats of human LigIV.
LigIV is part of a multiprotein complex and LigIV-binding
proteins may play a role in LigIV targeted degradation. The best-
known LigIV binding partner is XRCC4, which is required for the
stability and catalytic activity of LigIV in vitro and in vivo (Critchlow
et al. 1997; Grawunder et al., 1997). Because LigIV 1–748 lacks the
XRCC4-interaction domain of LigIV (767–783 (Grawunder et al.,
1998)) and is effectively degraded during adenovirus infection
(Fig. 1C), we conclude that the LigIV/XRCC4 interaction is not
required for targeted degradation of human LigIV during adenovirus
infection. LigIV’s BRCT-2 a2 helix does not contact XRCC4 (Wu
et al., 2009), but instead faces into solution, and is probably
accessible for protein–protein interactions. Because LigIV can either
bind XRCC4 or E4-34k, but not both (Jayaram et al., 2008) it is likely
that the XRCC4/LigIV complex is disassembled before LigIV poly-
ubiquitination. Whether disruption of the LigIV/XRCC4 complex is a
requirement for or a consequence of binding of viral proteins to
LigIV is currently unknown.
It is likely that yet unknown host proteins are targeted by the
adenovirus ubiquitin ligase. The identiﬁcation of the a2 helix as
required for the recognition of LigIV by the ubiquitin ligase
suggested that presence of this element might be useful in
identifying other adenovirus ubiquitin ligase targets. Therefore,
we examined the list of proteins believed to contain one or more
BRCT repeats to determine if other LigIV BRCT-1 a2-like helices
might be found. We screened BRCT containing proteins found in
the Pfam database (Finn et al., 2010) (PF00533) for an 8 amino
acid long region roughly where the a2 helix should be that
contains terminal hydrophobic residues, analogous to LigIV amino
acids I707 and L714, and a centrally located charged residue
analogous to K710. This search returned 30 candidate degradation
targets. Where published structural information was available we
manually examined the crystal structures for candidate targets to
conﬁrm the 8aa region was actually within a a2 helix. For
evaluation of candidate targets lacking published structural
information we used Jpred to predict the secondary structure
(Cole et al., 2008) of candidate BRCT repeats and manually
examined the output for a predicted alpha helix overlapping the
entire candidate 8aa region. This search yielded a single high
probability candidate for adenovirus-targeted degradation: topoi-
somerase-II binding protein 1 (TopBP1).
TopBP1 contains nine BRCT repeats, which are distributed
throughout the length of the protein (Yamane et al., 1997;
Rappas et al., 2011) and it is the second of these repeats that
contains a LigIV a2-like helix that matches our criteria for
adenovirus targeted degradation. Recent work by Blackford
showed that TopBP1 is not degraded during Ad5 infection, but
is a target for degradation by E4 34k and Cullin 2 in an E1b 55k-
independent mechanism employed by adenovirus type 12 (Ad12)
(Blackford et al., 2010). Ad12 E4 34k bound TopBP1, which is
similar to the observed binding of LigIV by Ad5 E4 34k (Jayaram
et al., 2008) and while these observations suggest similar
mechanisms for E4 34k-target recognition more needs to be done
before a bona ﬁde E4 34k-binding motif can be considered.
Is there a protein sequence or structural element common
to all adenovirus degradation targets that distinguishes themfrom other host proteins? Among identiﬁed adenovirus ubiquitin
ligase targets, only LigIV contains a BRCT repeat or a BRCT-1 a2
helix-like sequence, which indicates that other determinants
of degradation must exist. We have discussed the data
indicating that the N-terminal and C-terminal domains of LigIV
contain one or more elements necessary for adenovirus-targeted
degradation.
To date, work similar to that conducted here to determine the
speciﬁc requirements for degradation in adenovirus targets has
only been conducted on one other protein: p53. The region from
amino acids 24–28 in p53 was found to be sufﬁcient to promote
degradation of the p53 homolog p73 (Roth et al., 1998). This
region shares nothing obvious with the LigIV a2 helix. Each of the
adenovirus target proteins need to share only one requirement for
degradation: binding to the target selector protein E1b 55k. This
consensus motif would therefore likely be an E1b 55k interaction
domain. There is evidence, however, that Mre11, LigIV, and p53
may interact with E1b 55k in differing manners (Schwartz et al.,
2008). Identiﬁcation of the remaining determinants for LigIV
degradation, as well as determinants for Mre11 and BLM may
help us to develop a consensus sequence motif or a set of
structural requirements that identify potential targets for adeno-
viral degradation.
Adenovirus speciﬁcally promotes degradation LigIV, the only
member of the DNA Ligase family that interferes with viral
propagation, and does so without affecting other DNA ligases.
This speciﬁcity is conferred, in part, by the LigIV BRCT-1 a2 helix,
which is unique to LigIV. The lack of a LigIV BRCT-1 a2-like helix
in other adenovirus degradation targets and the observation that
LigIV contains additional elements required for degradation
indicates that multiple mechanisms exist for viral protein selec-
tion of degradation targets during adenovirus infection.Materials and methods
Cell culture. 293 (Graham et al., 1977) and Madin-Darby canine
kidney (MDCK) cells were propagated in Eagle’s minimal essential
media (Lonza) supplemented with 10% fetal bovine serum
(Gibco), penicillin (50 units/ml), and streptomycin (50 mg/ml).
Transfection, infection, and immunoblots. In a six-well plate,
293 cells were plated at 6105 cells per well, allowed to grow
overnight, then transfected with 2 mg of each DNA Ligase IV DNA,
E1b 55k DNA (where appropriate) and Lipofectamine 2000 for 4 h.
For cells that were subsequently infected with adenovirus, media
was replaced with 1 ml fresh serum-free Eagle’s Minimum Essen-
tial Medium (EMEM), and the cells were infected with adenovirus
at an MOI of 20 plaque-forming units (PFU) for 2 h. Media was
replaced with complete EMEMþ10% FBS, and cells were har-
vested 24 h after the beginning of transfection.
For immunoprecipitations, cells were harvested by scraping
into phosphate buffered saline (PBS) twenty-four hours after
beginning transfection, and lysed in 200 mL NET buffer (50 mM
Tris 8.0, 150 mM NaCl, 10% Glycerol, 1 mM DTT, 2 mM EDTA, 0.1%
Nonidet P40 (Sigma N3516)). 100 mL of lysate was incubated with
200 mL 2A6 (E1b 55k) hybridoma supernatant overnight at 4 1C.
The next day, 50 mL of 50% slurry of protein A Sepharose was
added, and rocked for 2 h at 4 1C. The beads were washed three
times for 15 min in 1 mL NET buffer at room temperature. Protein
sample buffer was added to the beads to liberate the immuno-
precipitated proteins, then the supernatant was loaded onto an 8%
SDS polyacrylamide gel. 7% of the soluble lysate used for each
immunoprecipitation was loaded onto a polyacrylamide gel as the
load fraction.
Mouse monoclonal antibodies used in immunoblots were the
following: Actin (1:400, Calbiochem), p53 (1:1000, Ab-6, Abcam),
T. Gilson et al. / Virology 428 (2012) 128–1351349E10 Myc hybridoma (Evan et al., 1985) supernatant (undiluted),
2A6 E1b 55k hybridoma (Sarnow et al., 1982) supernatant
(undiluted).
Site directed mutagenesis and chimeric genes. Mutagenesis of
pCR2.1-myc-LigIV-600–911 was carried out either by the Sigma
QuikChange Site-Directed Mutagenesis method as recommended
in the manual, or by the general megaprimer method. Oligonu-
cleotides are listed in Supplementary Table 1. Mutant clones were
sequenced and inserted into the pCI vector between NheI and
NotI sites for expression.
LigIII/LigIV chimeric genes were produced by domain swaps as
described in the Supplementary Methods.Funding
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